WASHINGTON (AP) — The Food and Drug Administration has approved a new long-acting inhaler drug from Boehringer Ingelheim to treat people with chronic lung disease.

The agency approved Striverdi Respimat for chronic obstructive pulmonary disease, which causes bronchitis and emphysema and affects about 24 million people in the U.S. The disease, which is most often caused by smoking, is the third leading cause of death in the U.S., according to the National Institutes of Health.